186 related articles for article (PubMed ID: 2788031)
1. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells.
Matthay KK; Abai AM; Cobb S; Hong K; Papahadjopoulos D; Straubinger RM
Cancer Res; 1989 Sep; 49(17):4879-86. PubMed ID: 2788031
[TBL] [Abstract][Full Text] [Related]
2. Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition.
Berinstein N; Matthay KK; Papahadjopoulos D; Levy R; Sikic BI
Cancer Res; 1987 Nov; 47(22):5954-9. PubMed ID: 3664498
[TBL] [Abstract][Full Text] [Related]
3. Uptake of antibody directed cytotoxic liposomes by CD3 on human T cells.
Gray AG; Morgan J; Linch DC; Huehns ER
Clin Exp Immunol; 1988 Apr; 72(1):168-73. PubMed ID: 3260836
[TBL] [Abstract][Full Text] [Related]
4. Antibody-directed liposomes: comparison of various ligands for association, endocytosis, and drug delivery.
Matthay KK; Heath TD; Badger CC; Bernstein ID; Papahadjopoulos D
Cancer Res; 1986 Oct; 46(10):4904-10. PubMed ID: 3756852
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia.
Hege KM; Daleke DL; Waldmann TA; Matthay KK
Blood; 1989 Nov; 74(6):2043-52. PubMed ID: 2679914
[TBL] [Abstract][Full Text] [Related]
6. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes.
Straubinger RM; Lopez NG; Debs RJ; Hong K; Papahadjopoulos D
Cancer Res; 1988 Sep; 48(18):5237-45. PubMed ID: 3409248
[TBL] [Abstract][Full Text] [Related]
7. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.
Simard P; Leroux JC
Int J Pharm; 2009 Nov; 381(2):86-96. PubMed ID: 19446624
[TBL] [Abstract][Full Text] [Related]
8. Endocytosis and de novo expression of major histocompatibility complex encoded class I molecules: kinetic and ultrastructural studies.
Machy P; Truneh A; Gennaro D; Hoffstein S
Eur J Cell Biol; 1987 Dec; 45(1):126-36. PubMed ID: 3443107
[TBL] [Abstract][Full Text] [Related]
9. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
10. Selection of tumor-specific internalizing human antibodies from phage libraries.
Poul MA; Becerril B; Nielsen UB; Morisson P; Marks JD
J Mol Biol; 2000 Sep; 301(5):1149-61. PubMed ID: 10966812
[TBL] [Abstract][Full Text] [Related]
11. Specific enhancement of drug delivery to AKR lymphoma by antibody-targeted small unilamellar vesicles.
Matthay KK; Heath TD; Papahadjopoulos D
Cancer Res; 1984 May; 44(5):1880-6. PubMed ID: 6713389
[TBL] [Abstract][Full Text] [Related]
12. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system.
Kakudo T; Chaki S; Futaki S; Nakase I; Akaji K; Kawakami T; Maruyama K; Kamiya H; Harashima H
Biochemistry; 2004 May; 43(19):5618-28. PubMed ID: 15134436
[TBL] [Abstract][Full Text] [Related]
13. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
14. Drug transfer into lymphoblasts mediated by liposomes bound to distinct sites on H-2 encoded I-A, I-E, and K molecules.
Machy P; Pierres M; Barbet J; Leserman LD
J Immunol; 1982 Nov; 129(5):2098-102. PubMed ID: 6811657
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
16. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
17. Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells.
Fonseca C; Moreira JN; Ciudad CJ; Pedroso de Lima MC; Simões S
Eur J Pharm Biopharm; 2005 Feb; 59(2):359-66. PubMed ID: 15661509
[TBL] [Abstract][Full Text] [Related]
18. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
[TBL] [Abstract][Full Text] [Related]
19. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
20. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.
Dinauer N; Balthasar S; Weber C; Kreuter J; Langer K; von Briesen H
Biomaterials; 2005 Oct; 26(29):5898-906. PubMed ID: 15949555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
